Expert Interviews

An expert discusses proactive management strategies for atopic dermatitis (AD), emphasizing daily gentle skin care, proper use of topical treatments, avoidance of outdated therapies such as routine antihistamines or steroids, and a shift toward personalized, flare-preventive care using newer therapeutic options.

An expert discusses practical strategies for assessing atopic dermatitis severity, highlighting simple yet effective tools such as the Investigator Global Assessment (IGA) scale, palm-based body surface area (BSA) estimation, and the Pruritus Numerical Rating Scale (NRS) to guide personalized treatment and improve symptom tracking in routine clinical care.

An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar conditions, and the critical role of education and skin care in effective management, particularly in primary care settings.

An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of collaboration between dermatology and primary care providers to improve patient outcomes.

Infectious disease expert Amesh Adalja, MD, outlines the biggest vaccine policy shifts of 2025, including changes to COVID-19 and flu vaccine recommendations.

Coauthor of a recent joint advisory, Jonathan Bonnet, MD, MPH, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.

Shagun Bindlish, MD, board member of the ADA, discusses how societal weight-related stigma contributes to mental health challenges faced by women with obesity.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.

Swenson focused on the precision afforded by digital tools in assessing human behavior and identifying preclinical signs of cognitive impairment.